Revelation Biosciences grants restricted stock to CEO and CFO tied to market cap goals

Revelation Biosciences, Inc. disclosed in an 8-K dated August 17, 2026 that its Compensation Committee approved restricted stock awards to Chief Executive Officer James Rolke and Chief Financial Officer Chester S. Zygmont, III under the company's Amended and Restated 2021 Equity Incentive Plan. The Compensation Committee approved the Restricted Stock Awards effective August 17, 2026, under the 2021 Equity Incentive Plan.¹ Rolke received an award covering 208,076 shares, and Zygmont received an award covering 208,073 shares.¹

Each award vests in four equal 25% tranches, with vesting tied to specific market capitalization thresholds or fixed anniversaries of the grant date, whichever comes first. The first tranche vests upon the company reaching a $30 million market capitalization for 20 consecutive trading days or on the second anniversary of the grant, the second tranche vests at $60 million market capitalization or the second anniversary, the third tranche vests at $90 million market capitalization or the fourth anniversary, and the fourth tranche vests at $120 million market capitalization or the fourth anniversary.¹ Market capitalization for these purposes is calculated by multiplying the closing share price on the principal exchange by the number of shares outstanding at the close of business on that trading day.¹

The awards become fully vested immediately before, and contingent on, a change in control as defined in the 2021 Plan, unless an individual agreement says otherwise.¹ Vesting also accelerates in full if the executive's service ends due to death, termination by the company without cause, or resignation by the executive for good reason.¹ Otherwise, unvested shares are forfeited if service ends for reasons including cause, disability, or retirement.¹